a, Mouse KP1 SCLC cells were engrafted into both flanks of B6129SF1 immunocompetent syngeneic mice and only right-side tumors were irradiated. Schematic of the depletion of CD8+ T cells following anti-CD8 antibody treatment. b, Analysis of splenic T cells by flow cytometry as in c. n = 1 experiment with n = 5 tumors. **P = 0.0079. c, Growth curves of KP1 SCLC allografts with the indicated treatments. n = 1 experiment with n = 5 mice except RT + anti-CD47/control and RT + anti-CD47/CD8 depletion (n = 4 mice). See independent experiment in Extended Data Fig. 2a. Irradiated tumors, ****P < 0.0001; ***P = 0.007, **P = 0.0016, *P = 0.0109; non-irradiated tumors, *P = 0.0159, *P = 0.0159, *P = 0.0159, *P = 0.0159. d, As in a with mouse KP3 cells engrafted into both flanks of NSG immunodeficient mice. e, Growth curves of KP3 allografts as in d with the indicated treatments. n = 1 experiment with n = 6 (control, anti-CD47 and RT) or n = 7 (RT + anti-CD47) tumors. Irradiated tumors, ****P < 0.0001, *P = 0.0229; non-irradiated tumors, ****P < 0.0001. f, As in a with human NCI-H82 and NJH29 SCLC cells were engrafted into NSG immunocompromised mice and only NJH29 tumors were irradiated. g, Growth curves of SCLC xenografts as in f with the indicated treatments. n = 1 experiment with n = 5 mice. Irradiated tumors, ***P = 0.0002, ***P = 0.0001; non-irradiated tumors, **P = 0.0079, **P = 0.0079. Two-tailed unpaired Student’s t-tests were performed in b. Two-tailed Student’s t-tests following two-way ANOVA were performed in c (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001), e (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001) and g (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001). Error bars represent s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Source data